Skip to main content

Advertisement

SpringerLink
Log in

Central Nervous System Involvement of Natural Killer and T Cell Neoplasms

  • Neuro-oncology (Y Umemura, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Peripheral natural killer (NK) and T cell neoplasms comprise approximately 10–15% of non-Hodgkin lymphomas. There are 27 different subtypes of peripheral NK and T cell neoplasms, each of which is relatively uncommon. Treatment has been largely extrapolated from case series, retrospective reports, and paradigms developed for the aggressive B cell lymphomas. This review explores the current knowledge of the characteristics, outcome, and treatment of CNS T cell and NK neoplasms.

Recent Findings

Primary and secondary CNS NK and T cell malignancies confer significant morbidity and poor prognosis. Despite clinical heterogeneity between the 27 subtypes, high-dose methotrexate–based regimens seem most effective overall. The role of prophylaxis against secondary CNS involvement remains controversial. Autologous stem cell transplant and immunotherapy are potential for promising future therapies.

Summary

Current understanding of incidence, outcome, and optimal treatment strategies for CNS T cell and NK neoplasms is limited, in large part due to their diversity and rarity. Prognosis is poor, except in a few reports of long-term survival in patients most often treated with combination therapy including high-dose methotrexate. A future prospective study on treatment and outcome in CNS T cell and NK neoplasms is needed to better define these diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Grommes C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol. 2017;35(21):2410–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21(2):266–72.

    Article  PubMed  Google Scholar 

  4. Chihara D, Fowler NH, Oki Y, Fanale MA, Nastoupil LJ, Westin JR, et al. Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis. Oncotarget. 2018;9(48):28897–902.

    Article  PubMed Central  PubMed  Google Scholar 

  5. • Shenkier TN, Blay JY, O'Neill BP, Poortmans P, Thiel E, Jahnke K, et al. Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol. 2005;23(10):2233–9 This is a large study on patients with primary CNS T cell lymphoma and describes outcome and general treatment regimens used in this patient population.

    Article  PubMed  Google Scholar 

  6. Menon MP, Nicolae A, Meeker H, Raffeld M, Xi L, Jegalian AG, et al. Primary CNS T-cell lymphomas: a clinical, morphologic, immunophenotypic, and molecular analysis. Am J Surg Pathol. 2015;39(12):1719–29.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Yang Y, Wickless H. Thinking about CNS metastasis in cutaneous lymphoma: analysis of existing data. Leuk Res Rep. 2017;8:14–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Miyata-Takata T, Takata K, Kato S, Hu LM, Noujima-Harada M, Chuang SS, et al. Clinicopathological analysis of primary central nervous system NK/T cell lymphoma: rare and localized aggressive tumour among extranasal NK/T cell tumours. Histopathology. 2017;71(2):287–95.

    Article  PubMed  Google Scholar 

  9. • Ellin F, Landström J, Jerkeman M, Relander T. Central nervous system relapse in peripheral T-cell lymphomas: a Swedish lymphoma registry study. Blood. 2015;126(1):36–41 This is a large cohort using information from the Swedish Lymphoma Registry which clarifies risk factors for CNS relapse and progression, as well as overall outcome.

    Article  CAS  PubMed  Google Scholar 

  10. Yi JH, Kim JH, Baek KK, Lim T, Lee DJ, Ahn YC, et al. Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma. Ann Oncol. 2011;22(7):1636–43.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. • Chihara D, Oki Y. Central nervous system involvement in peripheral T cell lymphoma. Curr Hematol Malig Rep. 2018;13(1):1–6 This is a review that includes new data from a previously reported retrospective study identifying risk factors and survival outcome for CNS relapse of peripheral T-cell lymphoma in 600 patients, organized by histologic subtype.

    Article  PubMed  Google Scholar 

  12. Gurion R, Mehta N, Migliacci JC, Zelenetz A, Moskowitz A, Lunning M, et al. Central nervous system involvement in T-cell lymphoma: a single center experience. Acta Oncol. 2016;55(5):561–6.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Rubio-Gonzalez B, Zain J, Rosen ST, Querfeld C. Clinical manifestations and pathogenesis of cutaneous lymphomas: current status and future directions. Br J Haematol. 2017;176(1):16–36.

    Article  PubMed  Google Scholar 

  14. Kaufman DK, Habermann TM, Kurtin PJ, O'Neill BP. Neurological complications of peripheral and cutaneous T-cell lymphomas. Ann Neurol. 1994;36(4):625–9.

    Article  CAS  PubMed  Google Scholar 

  15. Stein M, Farrar N, Jones GW, Wilson LD, Fox L, Wong RK, et al. Central neurologic involvement in mycosis fungoides: ten cases, actuarial risk assessment, and predictive factors. Cancer J. 2006;12(1):55–62.

    Article  PubMed  Google Scholar 

  16. Zhao G, Chamberlain MC, Khot SP, Shustov A, Olerud JE, Shinohara MM. Central nervous system involvement in cutaneous T-cell lymphoma: 2 illustrative cases and a review of current literature. Clin Lymphoma Myeloma Leuk. 2014;14(1):e25–30.

    Article  PubMed  Google Scholar 

  17. Keltner JL, Fritsch E, Cykiert RC, Albert DM. Mycosis fungoides. Intraocular and central nervous system involvement. Arch Ophthalmol. 1977;95(4):645–50.

    Article  CAS  PubMed  Google Scholar 

  18. Lindae ML, Luy J, Abel EA, Kaplan R. Mycosis fungoides with CNS involvement: neuropsychiatric manifestations and complications of treatment with intrathecal methotrexate and whole-brain irradiation. J Dermatol Surg Oncol. 1990;16(6):550–3.

    Article  CAS  PubMed  Google Scholar 

  19. Vu BA, Duvic M. Central nervous system involvement in patients with mycosis fungoides and cutaneous large-cell transformation. J Am Acad Dermatol. 2008;59(2 Suppl 1):S16–22.

    Article  PubMed  Google Scholar 

  20. Farcet JP, Gaulard P, Marolleau JP, Le Couedic JP, Henni T, Gourdin MF, et al. Hepatosplenic T-cell lymphoma: sinusal/sinusoidal localization of malignant cells expressing the T-cell receptor gamma delta. Blood. 1990;75(11):2213–9.

    CAS  PubMed  Google Scholar 

  21. Lavergne A, Brocheriou I, Delfau MH, Copie-Bergman C, Houdart R, Gaulard PH. Primary intestinal gamma-delta T-cell lymphoma with evidence of Epstein-Barr virus. Histopathology. 1998;32(3):271–6.

    Article  CAS  PubMed  Google Scholar 

  22. Foppoli M, Ferreri AJ. Gamma-delta t-cell lymphomas. Eur J Haematol. 2015;94(3):206–18.

    Article  CAS  PubMed  Google Scholar 

  23. Harada Y, Kato S, Komiya H, Shirota T, Mukai K, Hayashi T. Primary omental gamma/delta T-cell lymphoma involving the central nervous system. Leuk Lymphoma. 2004;45(9):1947–50.

    Article  CAS  PubMed  Google Scholar 

  24. Jones N, Gibb A, Irion L, Coupland S. Gamma-delta T-cell lymphoma of skin, eye and brain presenting with visual loss. Case Reports 2017; 2017:bcr–2017–219946.

  25. Harrington L, Sokol L, Holdener S, Shao H, Zhang L. Cutaneous gamma-delta T-cell lymphoma with central nervous system involvement: report of a rarity with review of literature. J Cutan Pathol. 2014;41(12):936–43.

    Article  PubMed  Google Scholar 

  26. Mooney KL, Choy W, Woodard J, Xian RR, Deal TM, Kendle RF, et al. Primary central nervous system gamma delta cytotoxic T-cell lymphoma. J Clin Neurosci. 2016;26:138–40.

    Article  PubMed  Google Scholar 

  27. Go RS, Wester SM. Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma: a systematic analysis of 156 patients reported in the literature. Cancer. 2004;101(6):1404–13.

    Article  PubMed  Google Scholar 

  28. Qiu Y, Zhang D, Zhang M. Long-term remission of subcutaneous panniculitis-like T-cell lymphoma with central nervous system involvement: a case report. Oncol Lett. 2016;12(1):611–4.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Karikari IO, Thomas KK, Lagoo A, Cummings TJ, George TM. Primary cerebral ALK-1-positive anaplastic large cell lymphoma in a child. Case report and literature review. Pediatr Neurosurg. 2007;43(6):516–21.

    Article  PubMed  Google Scholar 

  30. Chuang SS, Huang W, Lin CN, Chio CC, Tsai TC, Li CY, et al. Primary cerebral anaplastic large cell lymphoma containing abundant reactive histiocytes and eosinophils. A case report and literature review. Pathol Res Pract. 2001;197(9):647–52.

    CAS  PubMed  Google Scholar 

  31. Feldges A, Gerhard L, Reinhardt V, Budach V. Primary cerebral anaplastic T-cell-lymphoma (type Ki-1): review and case report. Clin Neuropathol. 1992;11(2):55–9.

    CAS  PubMed  Google Scholar 

  32. Kodama K, Hokama M, Kawaguchi K, Tanaka Y, Hongo K. Primary ALK-1-negative anaplastic large cell lymphoma of the brain: case report and review of the literature. Neuropathology. 2009;29(2):166–71.

    Article  PubMed  Google Scholar 

  33. Göçmen S, Kutlay M, Erikçi A, Atabey C, Sayan O, Haholu A. Central nervous system involvement of T-cell prolymphocytic leukemia diagnosed with stereotactic brain biopsy: case report. Turk J Haematol. 2014;31(1):75–8.

    Article  PubMed Central  PubMed  Google Scholar 

  34. Malkan UY, Gunes G, Yayar O, Demiroglu H, Yesilirmak A, Uner A. A T-cell prolymphocytic leukemia case with central nervous system involvement. Int J Clin Exp Med. 2015;8(8):14207–9.

    PubMed  PubMed Central  Google Scholar 

  35. Osuji N, Matutes E, Tjonnfjord G, Grech H, Del Giudice I, Wotherspoon A, et al. T-cell large granular lymphocyte leukemia: a report on the treatment of 29 patients and a review of the literature. Cancer. 2006;107(3):570–8.

    Article  PubMed  Google Scholar 

  36. Cheung CY, Ip AH, Iu PL, Lee EY, Kwong YL. Retinal and central nervous system involvement in T cell large granular lymphocyte leukaemia. Ann Hematol. 2015;94(7):1245–6.

    Article  PubMed  Google Scholar 

  37. Phillips AA, Harewood JCK. Adult T cell leukemia-lymphoma (ATL): state of the art. Curr Hematol Malig Rep. 2018;13(4):300–7.

    Article  PubMed  Google Scholar 

  38. Lymphoma Study Group (1984-1987). Major prognostic factors of patients with adult T-cell leukemia-lymphoma: a cooperative study. Leuk Res. 1991;15(2–3):81–90.

    Google Scholar 

  39. Pombo de Oliveira MS, Matutes E, Schulz T, Carvalho SM, Noronha H, Reaves JD, et al. T-cell malignancies in Brazil. Clinico-pathological and molecular studies of HTLV-I-positive and -negative cases. Int J Cancer. 1995;60(6):823–7.

    Article  CAS  PubMed  Google Scholar 

  40. Kitajima M, Korogi Y, Shigematsu Y, Liang L, Matsuoka M, Yamamoto T, et al. Central nervous system lesions in adult T-cell leukaemia: MRI and pathology. Neuroradiology. 2002;44(7):559–67.

    Article  CAS  PubMed  Google Scholar 

  41. Teshima T, Akashi K, Shibuya T, Taniguchi S, Okamura T, Harada M, et al. Central nervous system involvement in adult T-cell leukemia/lymphoma. Cancer. 1990;65(2):327–32.

    Article  CAS  PubMed  Google Scholar 

  42. Hsi AC, Kreisel FH, Frater JL, Nguyen TT. Clinicopathologic features of adult T-cell leukemias/lymphomas at a North American tertiary care medical center: infrequent involvement of the central nervous system. Am J Surg Pathol. 2014;38(2):245–56.

    Article  PubMed  Google Scholar 

  43. Ma WL, Li CC, Yu SC, Tien HF. Adult T-cell lymphoma/leukemia presenting as isolated central nervous system T-cell lymphoma. Case Rep Hematol. 2014;2014:917369.

    PubMed  PubMed Central  Google Scholar 

  44. Au WY, Weisenburger DD, Intragumtornchai T, Nakamura S, Kim WS, Sng I, et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood. 2009;113(17):3931–7.

    Article  CAS  PubMed  Google Scholar 

  45. Adams SV, Newcomb PA, Shustov AR. Racial patterns of peripheral T-cell lymphoma incidence and survival in the United States. J Clin Oncol. 2016;34(9):963–71.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. Cheung MM, Chan JK, Lau WH, Foo W, Chan PT, Ng CS, et al. Primary non-Hodgkin’s lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol. 1998;16(1):70–7.

    Article  CAS  PubMed  Google Scholar 

  47. • Kim SJ, Oh SY, Hong JY, Chang MH, Lee DH, Huh J, et al. When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type? Ann Oncol. 2010;21(5):1058–63 This paper attempted to identify risk factors for CNS invasion in extranodal natural killer (NK)/T-cell lymphoma, nasal type. It provides some guidance for when to consider CNS prophylaxis in patients with this malignancy.

    Article  CAS  PubMed  Google Scholar 

  48. Li X, Cheng Y, Zhang M, Yan J, Li L, Fu X, et al. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. J Hematol Oncol. 2018;11(1):15.

    Article  PubMed Central  PubMed  Google Scholar 

  49. Lau JC, Kosteniuk SE, Walker T, Iansavichene A, Macdonald DR, Megyesi JF. Operative complications with and without image-guidance: a systematic review and meta-analysis of the Ommaya reservoir literature. World Neurosurg 2018;122(9):404–414.

    Article  PubMed  Google Scholar 

  50. Schmitz N, Wu HS. Advances in the treatment of secondary CNS lymphoma. J Clin Oncol. 2015;33(33):3851–3.

    Article  CAS  PubMed  Google Scholar 

  51. Ferreri AJ, Donadoni G, Cabras MG, Patti C, Mian M, Zambello R, et al. High doses of antimetabolites followed by high-dose sequential chemoimmunotherapy and autologous stem-cell transplantation in patients with systemic B-cell lymphoma and secondary CNS involvement: final results of a multicenter phase II trial. J Clin Oncol. 2015;33(33):3903–10.

    Article  PubMed  Google Scholar 

  52. Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015;125(9):1403–10.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  53. Nayak L, Iwamoto FM, LaCasce A, Mukundan S, Roemer MGM, Chapuy B, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017;129(23):3071–3.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  54. Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017;129(17):2437–42.

    Article  CAS  PubMed  Google Scholar 

  55. Ghione P, Moskowitz AJ, De Paola NEK, Horwitz SM, Ruella M. Novel immunotherapies for T cell lymphoma and leukemias. Curr Hematol Malig Rep. 2018;13(6):494–506.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, et al. Non-Hodgkin’s lymphomas, version 4.2014. J Natl Compr Cancer Netw. 2014;12(9):1282–303.

    Article  CAS  Google Scholar 

  57. • Pro B, Perini G. Central nervous system prophylaxis in peripheral T-cell lymphoma. Blood. 2010;115(26):5427 A letter to the editor referencing data from M.D. Anderson Cancer Center on CNS relapse, arguing against the utility of CNS prophylaxis in these patients.

    Article  CAS  PubMed  Google Scholar 

  58. Gasco J, Franklin B, Fuller GN, Salinas P, Prabhu S. Multifocal epithelioid glioblastoma mimicking cerebral metastasis: case report. Neurocirugia (Astur). 2009;20(6):550–4.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, NewYork-Presbyterian Hospital, Weill Cornell Medicine, 528 East 68th Street, New York, NY, 10065, USA

    Ashley E. Aaroe

  2. Department of Neurology, Indiana University Health, Indiana University School of Medicine, 355 W. 16th St., Ste 3200, Indianapolis, IN, 46202, USA

    Kathryn S. Nevel

Authors
  1. Ashley E. Aaroe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kathryn S. Nevel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kathryn S. Nevel.

Ethics declarations

Conflict of Interest

The authors declare they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Neuro-oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aaroe, A.E., Nevel, K.S. Central Nervous System Involvement of Natural Killer and T Cell Neoplasms. Curr Oncol Rep 21, 40 (2019). https://doi.org/10.1007/s11912-019-0794-2

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-019-0794-2

Keywords

Search

Navigation